Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PROF
stocks logo

PROF

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.84M
+88.47%
-0.278
+38.75%
7.08M
+170.4%
-0.273
-24.07%
7.78M
+252%
-0.257
-50.64%
Estimates Revision
The market is revising Upward the revenue expectations for Profound Medical Corp. (PROF) for FY2025, with the revenue forecasts being adjusted by 5.95% over the past three months. During the same period, the stock price has changed by 63.83%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.95%
In Past 3 Month
Stock Price
Go Up
up Image
+63.83%
In Past 3 Month
Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.33 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.33 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.750
sliders
Low
11.00
Averages
11.33
High
12.00
Current: 6.750
sliders
Low
11.00
Averages
11.33
High
12.00
Raymond James
Michael Freeman
Strong Buy
to
Outperform
downgrade
$17 -> $11
2025-05-09
Reason
Raymond James
Michael Freeman
Price Target
$17 -> $11
2025-05-09
downgrade
Strong Buy
to
Outperform
Reason
Lake Street
Benjamin Haynor
Strong Buy
Maintains
$17 → $11
2025-04-23
Reason
Lake Street
Benjamin Haynor
Price Target
$17 → $11
2025-04-23
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Profound Medical Corp (PROF.O) is -6.53, compared to its 5-year average forward P/E of -8.29. For a more detailed relative valuation and DCF analysis to assess Profound Medical Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.29
Current PE
-6.53
Overvalued PE
-4.01
Undervalued PE
-12.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.88
Undervalued EV/EBITDA
-12.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.64
Current PS
0.00
Overvalued PS
28.09
Undervalued PS
7.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PROF News & Events

Events Timeline

(ET)
2025-11-28
07:46:48
Profound Medical Set to Introduce AI-Enhanced BPH Module
select
2025-11-16 (ET)
2025-11-16
05:54:07
Profound Medical announces Q3 earnings per share of 26 cents, below consensus estimate of 38 cents.
select
2025-11-13 (ET)
2025-11-13
16:42:13
Profound Medical announces Q3 earnings per share of 26 cents, below consensus estimate of 38 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
06:22 AMGlobenewswire
Profound Medical Receives RSNA Cum Laude Award, TULSA Procedure Significantly Reduces Patient Recovery Time
  • Honor Recognition: Profound Medical's Dr. Pejman Ghanouni received the Cum Laude award at the 2025 RSNA Annual Meeting for his research on the TULSA procedure, highlighting the company's academic influence in prostate cancer treatment and enhancing its brand reputation.
  • Clinical Data Advantage: The TULSA procedure allows patients to return to normal activities the day after treatment, compared to nearly three weeks for traditional robotic prostatectomy patients, significantly improving patient experience and potentially driving market demand.
  • CAPTAIN Trial Results: The CAPTAIN trial recruited 210 patients across 20 sites in the U.S. and beyond, with 69% receiving the TULSA procedure, providing robust clinical data that further validates TULSA's safety and efficacy.
  • Technological Innovation: The TULSA-PRO system integrates real-time MRI and AI technology to deliver personalized therapy, ensuring precise ablation of prostate tissue, marking a significant advancement in prostate disease treatment that could reshape the industry landscape.
[object Object]
Preview
5.0
12-01NASDAQ.COM
Profound Unveils AI-Driven BPH Module and Showcases New TULSA-PRO Clinical Findings at RSNA and SUO 2025

  • Launch of TULSA-AI Module: Profound Medical Corp. has introduced its TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) and presented new clinical data at major medical meetings, aiming to modernize treatment and expand its market significantly.

  • Clinical Advantages: The TULSA Procedure, which is incision-free, shows reduced risks of sexual dysfunction and incontinence compared to traditional treatments, with clinical trials indicating better outcomes in blood loss, recovery time, and post-operative pain.

  • Upcoming Presentations: The company will showcase various studies at the RSNA and SUO meetings, including comparisons of TULSA with robotic prostatectomy and the introduction of the AI-powered TULSA-PRO system.

  • Broader Applications: Beyond prostate treatments, Profound is also advancing its Sonalleve platform for various conditions, indicating potential for wider therapeutic applications in oncology and pain management.

[object Object]
Preview
3.5
11-28Newsfilter
Profound Medical Launches TULSA-AI Module, Targeting 600,000 Annual Patients
  • Technological Innovation: Profound Medical is set to launch its TULSA-AI Volume Reduction module at the RSNA meeting from November 30 to December 4, aimed at optimizing treatment for benign prostatic hyperplasia (BPH) patients, which is expected to significantly enhance patient experience and reduce complication risks.
  • Market Potential: By utilizing the TULSA-PRO system, physicians can efficiently handle multiple prostate cases in a single day, which is projected to triple Profound's total addressable market to approximately 600,000 patients annually, significantly expanding its market reach.
  • Clinical Advantages: The TULSA Procedure demonstrates superior outcomes in reducing risks of sexual function loss and incontinence, with CAPTAIN trial data showing advantages over robotic prostatectomy in terms of blood loss, length of stay, and postoperative recovery time, thereby driving strong demand from healthcare providers.
  • Future Outlook: Profound plans to present new data on TULSA-PRO for prostate cancer at both RSNA and the SUO meeting from December 2 to 5, indicating the company's ongoing innovation and leadership in the prostate disease treatment market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Profound Medical Corp (PROF) stock price today?

The current price of PROF is 6.75 USD — it has decreased -2.17 % in the last trading day.

arrow icon

What is Profound Medical Corp (PROF)'s business?

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

arrow icon

What is the price predicton of PROF Stock?

Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.33 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Profound Medical Corp (PROF)'s revenue for the last quarter?

Profound Medical Corp revenue for the last quarter amounts to 5.29M USD, increased 86.76 % YoY.

arrow icon

What is Profound Medical Corp (PROF)'s earnings per share (EPS) for the last quarter?

Profound Medical Corp. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Profound Medical Corp (PROF)'s fundamentals?

The market is revising Upward the revenue expectations for Profound Medical Corp. (PROF) for FY2025, with the revenue forecasts being adjusted by 5.95% over the past three months. During the same period, the stock price has changed by 63.83%.
arrow icon

How many employees does Profound Medical Corp (PROF). have?

Profound Medical Corp (PROF) has 131 emplpoyees as of December 05 2025.

arrow icon

What is Profound Medical Corp (PROF) market cap?

Today PROF has the market capitalization of 203.81M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free